Littérature scientifique sur le sujet « IRINOTECAN CANCER TREATMENT »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « IRINOTECAN CANCER TREATMENT ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "IRINOTECAN CANCER TREATMENT"
Aoki, Masahiko, Hirokazu Shoji, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa et al. « The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer. » Journal of Clinical Oncology 37, no 4_suppl (1 février 2019) : 124. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.124.
Texte intégralFalcone, Alfredo, Antonello Di Paolo, Gianluca Masi, Giacomo Allegrini, Romano Danesi, Monica Lencioni, Elisabetta Pfanner, Silvia Comis, Mario Del Tacca et Pierfranco Conte. « Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients ». Journal of Clinical Oncology 19, no 15 (1 août 2001) : 3456–62. http://dx.doi.org/10.1200/jco.2001.19.15.3456.
Texte intégralVanhoefer, Udo, Andreas Harstrick, Wolf Achterrath, Shousong Cao, Siegfried Seeber et Youcef M. Rustum. « Irinotecan in the Treatment of Colorectal Cancer : Clinical Overview ». Journal of Clinical Oncology 19, no 5 (1 mars 2001) : 1501–18. http://dx.doi.org/10.1200/jco.2001.19.5.1501.
Texte intégralBailly, Christian. « Irinotecan : 25 years of cancer treatment ». Pharmacological Research 148 (octobre 2019) : 104398. http://dx.doi.org/10.1016/j.phrs.2019.104398.
Texte intégralKockaya, Guvenc, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz et Saim Kerman. « Treatment cost of metastatic colon cancer in Turkey ». Farmeconomia. Health economics and therapeutic pathways 14, no 1 (30 janvier 2013) : 19–25. http://dx.doi.org/10.7175/fe.v14i1.472.
Texte intégralRadajewska, Anna, Helena Moreira, Dorota Bęben, Oliwia Siwiela, Anna Szyjka, Katarzyna Gębczak, Paulina Nowak et al. « Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment ». International Journal of Molecular Sciences 24, no 11 (31 mai 2023) : 9544. http://dx.doi.org/10.3390/ijms24119544.
Texte intégralAoki, Masahiko, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma et al. « Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer ». ESMO Open 4, no 3 (mai 2019) : e000488. http://dx.doi.org/10.1136/esmoopen-2019-000488.
Texte intégralKciuk, Mateusz, Beata Marciniak et Renata Kontek. « Irinotecan—Still an Important Player in Cancer Chemotherapy : A Comprehensive Overview ». International Journal of Molecular Sciences 21, no 14 (12 juillet 2020) : 4919. http://dx.doi.org/10.3390/ijms21144919.
Texte intégralSagawa, Tamotsu, Hironaga Satake, Koshi Fujikawa, Yukimasa Hatachi, Hisateru Yasui, Masahito Kotaka, Takeshi Kato et Akihito Tsuji. « Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane. » Journal of Clinical Oncology 36, no 4_suppl (1 février 2018) : 155. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.155.
Texte intégralShun, Yu-Ting, Hsien-Yung Lai, Yi-Ting Chuang et Hsuen-Fu Lin. « Successful Treatment of Irinotecan-Induced Muscle Twitching : A Case Report ». Clinical Medicine Insights : Case Reports 16 (janvier 2023) : 117954762211503. http://dx.doi.org/10.1177/11795476221150354.
Texte intégralThèses sur le sujet "IRINOTECAN CANCER TREATMENT"
Schiel, Marissa Ann. « Human carboxylesterase 2 splice variants expression, activity, and role in the metabolism of irinotecan and capecitabine / ». Thesis, Connect to resource online, 2009. http://hdl.handle.net/1805/1905.
Texte intégralTitle from screen (viewed on August 28, 2009). Department of Biochemistry and Molecular Biology, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): William Bosron. Includes vita. Includes bibliographical references (leaves 102-111).
Hinkle, David T. « CORRELATING IRINOTECAN AND CAPECITABINE TREATMENT FOR COLORECTAL CANCER TO GENE EXPRESSION, POLYMORPHISMS, AND CLINICAL OUTCOMES ». Thesis, 2011. http://hdl.handle.net/1805/2510.
Texte intégralColorectal cancer is the third most common type of cancer and the third most common cause of cancer-related mortality. There are three types of treatment available to patients, either individually or in combination. Treatments are radiation, chemotherapy, and surgery. In a Phase II clinical trial at IUSM, a multimodality approach was chosen. The patients with locally advanced rectal cancer received preoperative treatment with capecitabine and irinotecan (CPT-11) combination followed by chemoradiation with capecitabine and finally surgery to improve response and decrease local recurrence. Irinotecan and Capecitabine are both prodrugs activated in vivo to SN-38 and 5-FU, respectively. Identification of the molecular markers for 5-FU and Irinotecan efficacy and toxicity is important for the development of more efficient and less toxic treatment strategies for patients with colorectal cancer. The goal of this study was to determine the expression levels of the genes involved in activation and metabolism of capecitabine and irinotecan in pre and post treatment specimens from these patients. The genes quantitated by real-time PCR were carboxylesterase 1 and 2 (CES1 and CES2), thymidylate synthase (TS), β-glucoronidase (β-GUS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and topoisomerase I (Topo I). The UGT1A1*28 polymorphism in UDP glucuronosyltransferase 1 is associated with SN-38 toxicity. Therefore, the UGT1A1*28 polymorphism status in patients was determined by PCR-sequencing. Correlative analysis of gene expression and UGT1A1*28 mutation with clinical outcome in this Phase II study was completed.
DAS, NIVEDITA. « IN SILICO SCREENING OF QUERCETIN ANALOGUES AS POTENTIAL INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA FOR DIARRHEA MITIGATION IN IRINOTECAN CANCER TREATMENT ». Thesis, 2023. http://dspace.dtu.ac.in:8080/jspui/handle/repository/19909.
Texte intégralChen, Ming-Cheng, et 陳明正. « Molecular Mechanism of Resistance to Irinotecan in LoVo Colon Cancer Cells, Pharmacological Mechanism of Targeted Treatment by Thymoquinone and Mechanisms of Cancer Stem Cells and miRNAs ». Thesis, 2015. http://ndltd.ncl.edu.tw/handle/97204020698622003607.
Texte intégralMesserer, Corrie Lynn. « Liposomal encapsulation of irinotecan and potential for the use of liposomal drug in the treatment of liver metastases associated with advanced colorectal cancer ». Thesis, 2002. http://hdl.handle.net/2429/13284.
Texte intégralLivres sur le sujet "IRINOTECAN CANCER TREATMENT"
National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. London : NICE, 2002.
Trouver le texte intégralM, Lloyd Jones, et National Co-ordinating Centre for HTA (Great Britain), dir. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Alton : Core Research on behalf of NCCHTA, 2001.
Trouver le texte intégralLloyd, Jones M., National Co-ordinating Centre for HTA (Great Britain) et Health Technology Assessment Programme, dir. A Rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Southampton : NCCHTA, 2001.
Trouver le texte intégralChapitres de livres sur le sujet "IRINOTECAN CANCER TREATMENT"
Saltz, Leonard B. « Irinotecan in the Treatment of Colorectal Cancer ». Dans Colorectal Cancer, 513–24. Totowa, NJ : Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-160-2_28.
Texte intégralWagner, Lars. « Pediatric Neuroblastoma : Treatment with Oral Irinotecan and Temozolomide ». Dans Pediatric Cancer, 209–14. Dordrecht : Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2418-1_20.
Texte intégralFiorentini, Giammaria, Silvia Ricci Lucchi, Petros Giovanis, Maurizio Cantore, Stefano Guadagni et Giorgio Papiani. « Phase I Clinical Study of Irinotecan (CPT-11) Hepatic Arterial Infusion Chemotherapy in Hepatic Metastases from Colorectal Cancer : Preliminary Results ». Dans Multi-Treatment Modalities of Liver Tumours, 223–28. Boston, MA : Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0547-1_18.
Texte intégralOteyola, Ayodeji Ojo, Raffaele Pilla, Folasade Adesola Ola-Oladimeji et Omotayo Fagbuaro. « Natural Products Application and Combination Therapy in Colorectal Cancer Treatment ». Dans Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics, 72–94. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-9258-8.ch004.
Texte intégralActes de conférences sur le sujet "IRINOTECAN CANCER TREATMENT"
Davidson, David, Yunzhe Wang, Raquel Aloyz et Lawrence Panasci. « Abstract 4692 : ABT-888 synergizes treatment of colon cancer cell lines with irinotecan ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4692.
Texte intégralMorano, Federica, Salvatore Corallo, Ludovic Barault, Monica Niger, Rosa Berenato, Roberto Moretto, Giovanni Fucà et al. « Abstract CT095 : Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct095.
Texte intégralWestover, David, Xiang Ling, Xiaojun Liu, Hong Lam, Celine Gongora, Maguy Del Rio et Fengzhi Li. « Abstract 829 : The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer ». Dans Proceedings : AACR Annual Meeting 2014 ; April 5-9, 2014 ; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-829.
Texte intégralGiever, Thomas A., Paul S. Ritch, James P. Thomas, Lauren A. Wiebe, George B. Haasler, Mario G. Gasparri, David Johnstone, Candice A. Johnstone, Elizabeth M. Gore et Ben George. « Abstract 813 : A combination of cisplatin, irinotecan, and paclitaxel (CIP) as frontline treatment of patients with metastatic esophageal cancer (mEC) ». Dans Proceedings : AACR Annual Meeting 2014 ; April 5-9, 2014 ; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-813.
Texte intégralSachdev, Jasgit C., Ramesh K. Ramanathan, Natarajan Raghunand, Jaeyeon Kim, Stephan G. Klinz, Eliel Bayever, Jonathan B. Fitzgerald et Ronald L. Korn. « Abstract P5-01-06 : Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI) ». Dans Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium ; December 9-13, 2014 ; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-01-06.
Texte intégralKlinz, Stephan, Jinzi Zheng, Raquel De Souza, Manuela Ventura, Nancy Paz, David Hedley, David Jaffray et Jonathan Fitzgerald. « Abstract B47 : Nanoliposomal irinotecan (nal-IRI) is an active treatment and reduces hypoxia as measured through longitudinal imaging using [18F]FAZA-PET in an orthotopic patient-derived model of pancreatic cancer ». Dans Abstracts : AACR Special Conference on Pancreatic Cancer : Advances in Science and Clinical Care ; May 12-15, 2016 ; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.panca16-b47.
Texte intégralMoulder, S., M. Mita, C. Bradley, C. Rocha et L. Harris. « Abstract P6-15-01 : A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC) ». Dans Abstracts : Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010 ; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-15-01.
Texte intégralSachdev, JC, RK Ramanathan, N. Raghunand, C. Anders, P. Munster, S. Minton, D. Northfelt et al. « Abstract OT3-02-14 : A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398) ». Dans Abstracts : Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium ; December 8-12, 2015 ; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-ot3-02-14.
Texte intégral